FibroBiologics terminates sublease early, saves $0.8M in future rent; moves HQ to Houston

FibroBiologics, Inc.

Sublease buyout agreement with United Fire & Casualty terminates sublease effective April 2, 2026, 18 months early.
Single exit payment of $45,108.25 resolves remaining rent obligations; original sublease ran through Nov 30, 2027.
Expected savings of approx. $0.8 million in future rent payments.
Consolidation follows 2025 opening of new 10,000+ sq ft lab and office facility.
Principal executive offices relocated to 9350 Kirby Drive, Suite 300, Houston, TX 77054.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

FibroBiologics, Inc. terminated Sublease Buyout Agreement with United Fire & Casualty Co. valued at Single payment of $45,108.25; expected savings of approximately $0.8 million in future rent payments (effective 2026-04-03).

Action: termination
Agreement: lease
Counterparty: United Fire & Casualty Co.
Value: Single payment of $45,108.25; expected savings of approximately $0.8 million in future rent payments
Effective: 2026-04-03

Exact text from the filing

On April 3, 2026, FibroBiologics, Inc. (the “Company”) entered into a Sublease Buyout Agreement (the “Lease Termination Agreement”) with United Fire & Casualty Co. (doing business as United Fire Group) (the “Sublandlord”) to terminate that certain Sublease Agreement, which was effective as of October 5, 2022 (“Sublease”), pursuant to which Sublandlord subleased to the Company certain premises located at the third floor of 455 E. Medical Center Blvd, Webster, County of Harris, Texas 77598.

View on SEC.gov

301 material agreements filed in the last 30 days. Browse all material agreements →

FibroBiologics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-149865

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.